FOXO4-DRI
Also known as: FOXO4 DRI, FOXO4-D-Retro-Inverso, FOXO4-DRI peptide, D-retro-inverso FOXO4 peptide
4 notable studies · 4 references
TLDR
FOXO4-DRI is an experimental D-retro-inverso senolytic peptide that disrupts FOXO4-p53 interactions and selectively eliminates certain senescent cells in preclinical models, producing intriguing improvements in age-associated tissue dysfunction in mice but without established human efficacy or safety.
Research Supports
- Studied as a senolytic for selectively inducing apoptosis in senescent cells
- Investigated for effects on age-associated tissue dysfunction in mouse models
- Studied for disrupting the FOXO4-p53 protein interaction at the molecular level
- Investigated for effects on vascular aging and endothelial-cell senescence
- Studied for effects on senescent fibroblasts in keloid-tissue models
Observations Reported in Research
- Selectively induced apoptosis in senescent cells and improved tissue function and age-associated phenotypes in aged and progeroid mice (Baar et al., 2017)
- Structural study identified the p53 transactivation domain (TAD2) as the direct FOXO4-DRI interaction site (Bourgeois et al., 2025)
- Promoted apoptosis in senescent endothelial cells and improved aortic function in aged/progeroid mice (Hu et al., 2026)
- Promoted apoptosis in senescent keloid fibroblasts via changes in p53 localization in organ-culture models (Kong et al., 2025)
- No established human clinical efficacy evidence exists for FOXO4-DRI
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Synthetic D-retro-inverso peptide; FOXO4-p53 protein-interaction inhibitor; experimental senolytic peptide
FOXO4-DRI is an experimental senolytic peptide designed to selectively trigger death of certain senescent cells. Senescent cells are cells that have permanently stopped dividing but remain metabolically active. Some release inflammatory and tissue-altering factors collectively called the SASP — senescence-associated secretory phenotype. Senescent cells accumulate with age and in many diseases. FOXO4-DRI takes an unusual approach: FOXO4 + p53 interaction ↓ helps some senescent cells resist apoptosis ↓ FOXO4-DRI disrupts that interaction ↓ p53 is redistributed ↓ senescent-cell apoptosis. The landmark 2017 study found that FOXO4-DRI selectively induced apoptosis in senescent cells and improved several age-associated phenotypes in mice. And the mechanism has become considerably better defined since then: a 2025 structural study directly characterized how FOXO4 and FOXO4-DRI interact with the p53 transactivation domain. But: FOXO4-DRI has not been demonstrated to reverse human aging. The evidence remains preclinical.
What Is FOXO4-DRI?
FOXO4 is a member of the forkhead box O family of transcription factors. Researchers discovered that senescent cells display an interaction between FOXO4 and p53. That interaction appears to help retain p53 within the nucleus of certain senescent cells, contributing to their resistance to apoptosis. Researchers therefore designed a peptide corresponding to a FOXO4 interaction region. But instead of constructing it from ordinary L-amino acids, they created a D-retro-inverso peptide. This design reverses the peptide sequence while using D-amino acids, helping preserve aspects of the original side-chain topology while increasing resistance to enzymatic degradation. Hence: DRI = D-retro-inverso.
What Are Researchers Studying?
Cellular senescence
Cellular senescence is the central research area. Senescence can be useful. It participates in tumor suppression, wound healing, development, and damage responses. But persistent accumulation of senescent cells can also contribute to chronic inflammation and declining tissue function. FOXO4-DRI was designed to remove certain senescent cells rather than merely suppress their secretions. That's why it's classified as a senolytic.
Aging and healthspan
The landmark 2017 study tested FOXO4-DRI in naturally aged and prematurely aged mice. Eliminating senescent cells produced improvements in several measured phenotypes, including aspects of physical activity, fur density, kidney function, and tissue homeostasis. This provided striking proof-of-concept evidence that targeting senescent-cell survival could affect age-associated dysfunction. Improving age-associated phenotypes in mice ≠ reversing human aging. And healthspan improvement ≠ lifespan extension.
p53 biology
p53 is famous as a tumor-suppressor protein, but its biology extends well beyond cancer. It influences DNA-damage responses, cell-cycle arrest, senescence, and apoptosis. FOXO4-DRI doesn't simply "activate p53." Instead, it disrupts a specific FOXO4-p53 protein interaction associated with senescent-cell survival. The 2025 structural work showed that FOXO4-DRI interacts with the disordered p53 TAD2 region, providing substantially stronger molecular evidence for the proposed mechanism.
Vascular aging
This research area has become more interesting recently. A 2026 study examined FOXO4-DRI in senescent endothelial cells and aged/progeroid mice. Researchers reported improved aortic function and reduced markers of vascular aging while further implicating p53-related apoptotic signaling. This extends FOXO4-DRI research beyond the original generalized aging models. It remains preclinical.
Fibrosis and pathological scarring
Senescent cells can contribute to persistent pathological tissue environments. A 2025 study investigated keloid fibroblasts, finding evidence of senescent fibroblast populations and altered p53 signaling. FOXO4-DRI promoted apoptosis in experimental senescent keloid fibroblasts and organ-culture models. That suggests possible applications outside generalized aging. It is not evidence that FOXO4-DRI treats human keloids clinically.
Senolytic therapeutics
FOXO4-DRI belongs to the broader field of senolytics. Other experimental approaches include compounds targeting BCL-2/BCL-xL, PI3K/AKT, p53-associated pathways, and tyrosine kinases. The interesting feature of FOXO4-DRI is its attempt to exploit a protein-protein interaction enriched in senescent-cell survival rather than broadly inhibiting a conventional enzyme.
How Does It Work?
The simplified model is: Cell becomes senescent ↓ increased/altered FOXO4-p53 interaction ↓ p53 retained in nuclear structures ↓ senescent cell resists apoptosis ↓ FOXO4-DRI competes with FOXO4 for p53 interaction ↓ p53 localization/signaling changes ↓ apoptotic pathways activated ↓ senescent-cell death. The original experiments suggested relative selectivity for senescent cells. Recent structural work substantially strengthens the physical interaction component of this model. But "selective" should not be interpreted as incapable of affecting healthy human tissues. That has not been established clinically.
What Does the Research Show?
Human research
There is currently no established human clinical efficacy evidence for FOXO4-DRI. Human cells and tissues can be used experimentally. That is different from administering the compound to people. There is no established clinical evidence that FOXO4-DRI: - Extends human lifespan - Reverses biological age - Improves human kidney function - Prevents dementia - Improves cardiovascular outcomes - Reverses frailty - Treats keloids - Prevents age-related disease This profile should therefore carry a clear PRECLINICAL evidence badge.
Animal research
Animal evidence is the major source of therapeutic interest. The foundational mouse work reported improvements in tissue homeostasis and age-associated phenotypes following targeted senescent-cell apoptosis. More recent mouse work has expanded investigation into vascular aging and endothelial senescence. Promising? Absolutely. Human anti-aging treatment? Not established.
In-vitro research
Mechanistic cellular evidence is increasingly substantial. Researchers have studied: - FOXO4-p53 binding - p53 localization - Apoptosis - Senescent-cell selectivity - Endothelial-cell senescence - Fibroblast senescence The 2025 structural study is particularly valuable because it characterized the molecular interaction rather than relying only on downstream cellular behavior.
Notable Studies
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
animalResearchers identified FOXO4-p53 interaction as an important survival mechanism in senescent cells and developed FOXO4-DRI to disrupt it. FOXO4-DRI selectively induced apoptosis in senescent cells in experimental systems and improved several measures of tissue function and age-associated phenotype in naturally aged and progeroid mice.
Limitations: Cell and mouse research only. Improvements in mouse aging phenotypes do not demonstrate human rejuvenation, lifespan extension, or clinical safety.
View publication →The Disordered p53 Transactivation Domain Is the Target of FOXO4 and the Senolytic Compound FOXO4-DRI
in-vitroResearchers used structural and biophysical approaches to characterize FOXO4-p53 and FOXO4-DRI-p53 interactions. The work identified the p53 transactivation domain—particularly TAD2—as a direct interaction region and showed how the FOXO4-derived and cell-penetrating portions of FOXO4-DRI contribute to binding.
Limitations: Mechanistic molecular research does not establish therapeutic efficacy, selectivity, pharmacokinetics, or safety in humans.
View publication →FOXO4-DRI Induces Keloid Senescent Fibroblast Apoptosis by Promoting Nuclear Exclusion of Upregulated p53-Serine 15 Phosphorylation
humanResearchers identified senescent fibroblast populations and altered p53 signaling in keloids. FOXO4-DRI promoted apoptosis in experimental senescent fibroblasts and keloid organ cultures through changes involving phosphorylated p53 localization.
Limitations: Human-derived tissue studied outside the body is not a human clinical trial. Clinical efficacy and safety for keloids remain unknown.
View publication →FOXO4-DRI Regulates Endothelial Cell Senescence via the P53 Signaling Pathway
animalResearchers investigated FOXO4-DRI in senescent endothelial cells and naturally aged/progeroid mice. Treatment promoted apoptosis of senescent endothelial cells and was associated with improved aortic function and reduced vascular-aging phenotypes.
Limitations: Preclinical models only. These findings don't demonstrate prevention or treatment of human cardiovascular aging.
View publication →What We Still Don't Know
• Human safety • Human pharmacokinetics • Effective human exposure • Biodistribution • Long-term consequences of senescent-cell depletion • Which senescent-cell populations are beneficial versus harmful • Whether selectivity persists in humans • Effects on wound healing • Effects on tissue regeneration • Effects on immune function • Effects on tumor surveillance • Whether repeated treatment would be necessary • Whether eliminating senescent cells improves human lifespan or healthspan • Whether benefits differ dramatically by tissue • Whether research-market FOXO4-DRI corresponds to material used in published studies
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the FOXO4-DRI research with you.
Get the Aminodex FOXO4-DRI Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Baar MP, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017.
- Bourgeois B, et al. The Disordered p53 Transactivation Domain Is the Target of FOXO4 and the Senolytic Compound FOXO4-DRI. Nature Communications. 2025.
- Kong YX, et al. FOXO4-DRI Induces Keloid Senescent Fibroblast Apoptosis by Promoting Nuclear Exclusion of Upregulated p53-Serine 15 Phosphorylation. Communications Biology. 2025.
- Hu Z, et al. FOXO4-DRI Regulates Endothelial Cell Senescence via the P53 Signaling Pathway. 2026.
Supplier Listings
A directory of relevant research suppliers for this compound is not yet available.